Prognostic value of myocardial perfusion imaging by cadmium zinc telluride single-photon emission computed tomography in patients with suspected or known coronary artery disease: a systematic review and meta-analysis.
CZT-SPECT
Coronary artery disease
Meta-analysis
Myocardial perfusion imaging
Outcome
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
16
05
2023
accepted:
13
07
2023
medline:
4
10
2023
pubmed:
22
7
2023
entrez:
22
7
2023
Statut:
ppublish
Résumé
Aim of this study was to define the prognostic value of stress myocardial perfusion imaging by cadmium zinc telluride (CZT) single-photon emission computed tomography (SPECT) for prediction of adverse cardiovascular events in patients with known or suspected coronary artery disease (CAD). Studies published until November 2022 were identified by database search. We included studies using stress myocardial perfusion imaging by CZT-SPECT to evaluate subjects with known or suspected CAD and providing primary data of adverse cardiovascular events. Total of 12 studies were finally included recruiting 36,415 patients. Pooled hazard ratio (HR) for the occurrence of adverse events was 2.17 (95% confidence interval, CI, 1.78-2.65) and heterogeneity was 66.1% (P = 0.001). Five studies reported data on adjusted HR for the occurrence of adverse events. Pooled HR was 1.69 (95% CI, 1.44-1.98) and heterogeneity was 44.9% (P = 0.123). Seven studies reported data on unadjusted HR for the occurrence of adverse events. Pooled HR was 2.72 (95% CI, 2.00-3.70). Nine studies reported data useful to calculate separately the incidence rate of adverse events in patients with abnormal and normal myocardial perfusion. Pooled incidence rate ratio was 2.38 (95% CI, 1.39-4.06) and heterogeneity was 84.6% (P < 0.001). The funnel plot showed no evidence of asymmetry (P = 0.517). At meta-regression analysis, we found an association between HR for adverse events and presence of angina symptoms and family history of CAD. Stress myocardial perfusion imaging by CZT-SPECT is a valuable noninvasive prognostic indicator for adverse cardiovascular events in patients with known or suspected CAD.
Sections du résumé
BACKGROUND
Aim of this study was to define the prognostic value of stress myocardial perfusion imaging by cadmium zinc telluride (CZT) single-photon emission computed tomography (SPECT) for prediction of adverse cardiovascular events in patients with known or suspected coronary artery disease (CAD).
METHODS AND RESULTS
Studies published until November 2022 were identified by database search. We included studies using stress myocardial perfusion imaging by CZT-SPECT to evaluate subjects with known or suspected CAD and providing primary data of adverse cardiovascular events. Total of 12 studies were finally included recruiting 36,415 patients. Pooled hazard ratio (HR) for the occurrence of adverse events was 2.17 (95% confidence interval, CI, 1.78-2.65) and heterogeneity was 66.1% (P = 0.001). Five studies reported data on adjusted HR for the occurrence of adverse events. Pooled HR was 1.69 (95% CI, 1.44-1.98) and heterogeneity was 44.9% (P = 0.123). Seven studies reported data on unadjusted HR for the occurrence of adverse events. Pooled HR was 2.72 (95% CI, 2.00-3.70). Nine studies reported data useful to calculate separately the incidence rate of adverse events in patients with abnormal and normal myocardial perfusion. Pooled incidence rate ratio was 2.38 (95% CI, 1.39-4.06) and heterogeneity was 84.6% (P < 0.001). The funnel plot showed no evidence of asymmetry (P = 0.517). At meta-regression analysis, we found an association between HR for adverse events and presence of angina symptoms and family history of CAD.
CONCLUSIONS
Stress myocardial perfusion imaging by CZT-SPECT is a valuable noninvasive prognostic indicator for adverse cardiovascular events in patients with known or suspected CAD.
Identifiants
pubmed: 37480369
doi: 10.1007/s00259-023-06344-8
pii: 10.1007/s00259-023-06344-8
pmc: PMC10547640
doi:
Substances chimiques
CdZnTe
0
Cadmium
00BH33GNGH
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3647-3658Informations de copyright
© 2023. The Author(s).
Références
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Nucl Med Rev Cent East Eur. 2022;25(2):119-126
pubmed: 35848537
Ann Intern Med. 2006 Mar 21;144(6):427-37
pubmed: 16549855
Open Med. 2009;3(3):e123-30
pubmed: 21603045
J Nucl Cardiol. 2009 Mar-Apr;16(2):255-76
pubmed: 19242769
Eur J Nucl Med Mol Imaging. 2020 Jul;47(7):1705-1712
pubmed: 31848673
Curr Cardiol Rep. 2019 May 18;21(7):57
pubmed: 31104158
J Nucl Cardiol. 2021 Dec;28(6):2927-2936
pubmed: 32500175
J Nucl Cardiol. 2012 Dec;19(6):1113-23
pubmed: 23065414
Antimicrob Agents Chemother. 2004 Aug;48(8):2787-92
pubmed: 15273082
Eur Heart J Cardiovasc Imaging. 2016 Jun;17(6):591-5
pubmed: 26985078
J Nucl Cardiol. 2009 Nov-Dec;16(6):927-34
pubmed: 19688410
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Nucl Cardiol. 2020 Jun;27(3):1010-1021
pubmed: 29923104
Int J Cardiovasc Imaging. 2019 Jun;35(6):1163-1167
pubmed: 30680654
Int J Cardiovasc Imaging. 2016 Feb;32(2):355-361
pubmed: 26424491
J Nucl Cardiol. 2022 Feb;29(1):141-154
pubmed: 33389636
JACC Cardiovasc Imaging. 2020 Mar;13(3):774-785
pubmed: 31202740
Eur Heart J Cardiovasc Imaging. 2014 Mar;15(3):275-83
pubmed: 23975570
J Nucl Cardiol. 2021 Dec;28(6):2827-2839
pubmed: 32383083
Am J Cardiol. 2007 Aug 1;100(3):436-41
pubmed: 17659924
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Eur J Nucl Med Mol Imaging. 2016 Dec;43(13):2423-2432
pubmed: 27542010
Biometrics. 2000 Jun;56(2):455-63
pubmed: 10877304
Comput Math Methods Med. 2021 Oct 16;2021:5288844
pubmed: 34697554
Eur J Nucl Med Mol Imaging. 2022 Dec;50(1):160-167
pubmed: 36053295
Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):718-28
pubmed: 26686336
J Nucl Cardiol. 2022 Apr;29(2):727-736
pubmed: 32929639
J Nucl Cardiol. 2021 Dec;28(6):3025-3037
pubmed: 33000403
J Nucl Med. 2017 Sep;58(9):1459-1463
pubmed: 28450561
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3647-3658
pubmed: 37480369
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1544-1552
pubmed: 34773166
J Nucl Cardiol. 2021 Apr;28(2):698-715
pubmed: 31089962
Eur Heart J Cardiovasc Imaging. 2022 Feb 22;23(3):372-380
pubmed: 33247905
Eur Heart J Cardiovasc Imaging. 2015 Dec;16(12):1289-98
pubmed: 25902767
J Nucl Cardiol. 2023 Apr;30(2):684-701
pubmed: 35918592
BMC Med Res Methodol. 2009 Dec 04;9:80
pubmed: 19961608
J Nucl Med. 2004 May;45(5):912-21
pubmed: 15136643
J Nucl Cardiol. 2004 Mar-Apr;11(2):171-85
pubmed: 15052249
J Nucl Cardiol. 2022 Aug;29(4):1686-1697
pubmed: 34350553
Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1004-11
pubmed: 25711177
Eur J Nucl Med Mol Imaging. 2016 Feb;43(2):296-301
pubmed: 26392197
Circulation. 2007 Jun 5;115(22):2870-5
pubmed: 17548743
J Nucl Cardiol. 2017 Feb;24(1):245-251
pubmed: 27510176